CLVS News and Press, Clovis Oncology Inc. From 06/06/22

Penny stocks are great tools to make money in the stock market. While they don’t come without risk, there are plenty of ways to ensure you find the top names to watch. One of the first steps is looking for specific catalysts. These could be anything from unusual trading activity to m...

Clovis Oncology (NASDAQ:CLVS) said on Monday its therapy Rubraca significantly improved progression-free survival compared with placebo in women with advanced ovarian cancer in a late-stage trial. Stock up 6.3% before the bell. The trial, dubbed Athena-Mono, met its primar...

Bluebird Bio (BLUE), Clovis Oncology (NASDAQ:CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out of cash within the next six months. The analysis of 118 companies developing cancer medications exclu...

ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend. In H2 this year, ImmunoGen is set to release a flurry of catalysts. For further details see: ImmunoGen: An Inflection Po...

Biotech stocks have taken a beating to start the year, with the S&P Biotech Industry Index down more than 49% so far. That doesn't mean that investors should give up on the sector, however. These stocks are known for volatility because all it takes is one blockbuster drug to upl...

H.C. Wainwright has downgraded Clovis Oncology (NASDAQ:CLVS) to neutral from buy over concerns about a potential launch of Rubraca (rucaparib) as a first-line ovarian cancer treatment. Shares are down 30% in Friday afternoon trading. Analyst Edward White noted that the company recen...

This week has been a tough one for stocks, but it's been especially tough for specialty biotech Clovis Oncology (NASDAQ: CLVS) . Following the release of its first-quarter results and operational update, the company's shares traded down sharply, and they have yet to recover. Accordi...

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time. The conference will be held at the Encore hotel...

ArcelorMittal S.A. (NYSE:MT) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $3.41 (+76.7% Y/Y) and the consensus Revenue Estimate is $20.83B (+28.7% Y/Y). Over the last 1 year, MT has beaten EPS estimates 75% of the time an...

Gainers: Sharps Technology (STSS) +43%. TransMedics Group (TMDX) +30%. Super Micro Computer (SMCI) +25%. CarParts.com (PRTS) +25%. Superior Industries International (SUP) +22%. Livent (LTHM) +23%. Bright Health Group (BHG) +21%. eHealth (EHTH) +19%. BlueLinx Holdings (BXC) +18%. Kimball Inter...